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PURPOSE. The goal of this study was to examine the mechanism behind the unique differential
action of transforming growth factor b3 (TGF-b3) and TGF-b1 on SMA expression. It was our
hypothesis that platelet-derived growth factor receptor a (PDGFRa) played a key role in
determining TGF-b3’s response to wounding.
METHODS. A stable cell line, human corneal fibroblast (HCF)-P, was created from HCFs by
knocking down PDGFRa expression using a lentivirus-delivered shRNA sequence. A three-
dimensional (3D) in vitro model was constructed by culturing HCF or HCF-P on poly-transwell
membranes for 4 weeks in the presence and absence of 0.1 ng/mL TGF-b1 or -b3. At the end
of 4 weeks, the constructs were processed for immunofluorescence and reverse
transcription–quantitative polymerase chain reaction (RT-qPCR). In addition, HCF and HCF-
P cell migration was evaluated.
RESULTS. In HCF, TGF-b3 treatment resulted in significantly lower a-smooth muscle actin
(SMA) mRNA expression and immunolocalization when compared to TGF-b1, while in HCF-
P, both TGF-b1 and -b3 treatment increased the SMA mRNA expression and immunolocal-
ization compared to both the untreated HCF-P control and TGF-b3-treated HCF. Human
corneal fibroblast-P also had a lower migration rate and construct thickness when compared
to HCF.
CONCLUSIONS. These results show that TGF-b3 decreases SMA in HCF, while remarkably
increasing SMA in HCF-P, thus indicating that the presence or absence of PDGFRa elicits
contrasting responses to the same TGF-b3 treatment. Understanding the role of PDGFRa in
TGF-b3’s ability to stimulate SMA may potentially help in understanding the differential
functions of TGF-b1 and TGF-b3 in corneal wound healing.
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After a corneal injury, the cornea may scar (fibrosis) andbecome opaque, thus impairing vision and even leading to
blindness. The process of corneal wound healing is complex
and involves a variety of cytokines, growth factors, and
proteases, which interact to regulate key phases of corneal
healing. One such growth factor, transforming growth factor b
(TGFb), has emerged as a key component of the corneal
wound-healing response.1 Transforming growth factor b has
been found to regulate the transformation of quiescent
keratocytes into activated fibroblasts, upregulate the secretion
of extracellular matrix (ECM) materials, and enhance the
formation of stress fibers.2 Furthermore, TGFb directly stimu-
lates the transformation of activated fibroblasts into myofibro-
blasts, which are filled with a smooth muscle actin (SMA) that
forms microfilaments and are a major source of light scattering
in corneal scars.3,4
Transforming growth factor b isoforms, in particular, TGF-b1
and -b3 (T1 and T3, respectively), have been shown to play
different roles that are key in determining the wound-healing
outcome. For instance, T1 has been found to be a regulator of
fibrosis and scarring, while T3 does not stimulate this scarring
effect in skin, lung, and kidney,5–7 and in some cases, even
stimulates scar-free healing.8,9
Like the TGFbs, there is also an extensive literature set
associating platelet-derived growth factors (PDGFs) with
fibrosis in different scarring models.10 The intrinsic affinity of
each PDGF isoform for the two PDGFR subunits determines the
type of receptor dimer that is assembled. Platelet-derived
growth factor B is the universal ligand, whereas PDGFAB and
PDGFC assemble and activate only PDGFRa homodimers and
PDGFRab heterodimers. Platelet-derived growth factor D
activates PDGFRb homodimers, while PDGFA only activates
PDGFRa homodimers.11 Recently, it has been suggested that
these PDGF receptors were activated through an autocrine
loop leading to keratocyte proliferation and myofibroblast
differentiation.12 In addition, PDGFRa co-localizes with SMA,
and PDGF-blocking antibodies inhibit the TGFb-induced
differentiation of keratocytes to myofibroblasts.12
These studies led to the logical supposition that PDGFs
contribute to SMA expression by differentially activating the
PDGFRs. Therefore, in this study, we utilized our three-
dimensional (3D) cell-culture model13 to study the relationship
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between T1’s and T3’s interaction with PDGFR and determined
if this interaction is responsible for their differential stimulation
of SMA expression.
MATERIALS AND METHODS
Generation of Stable PDGFRa Knockdown Cell
Line (HCF-P)
Human corneal fibroblasts (HCFs) were isolated as previously
described14 from human corneas obtained from the National
Disease Research Interchange (NDRI; Philadelphia, PA, USA).
All research adhered to the tenets of the Declaration of
Helsinki. Once isolated, HCFs were plated on six-well plates
and grown to 75% confluency in media (Eagle’s minimum
essential media [EMEM]; American Type Culture Collection
[ATCC], Manassas, VA, USA) with 10% serum (fetal bovine
serum [FBS]; Atlanta Biologicals, Flowery Branch, GA, USA)
and 1% Antibiotic-Antimycotic (ABAM; Thermo Fisher Scientif-
ic, Waltham, MA, USA).
To generate the HCF-P cell line, HCFs were infected with a
PDGFRa shRNA lentivirus, as previously described.15 In brief,
HCFs were grown to ~70% confluence in six-well cell culture
plates. Media with lentivirus particles (pCMV-dR8.91, VSV-G/
pMD2.G, hairpin-pLKO.1 vector containing the PDGFRa
shRNA oligo [Dana Farber Cancer Institute/Harvard Medical
School, Boston, MA, USA]), and Polybrene (4 lg/mL; Sigma-
Aldrich Corp., St. Louis, MO, USA), which was used to improve
the transduction efficiency, was prepared. This media was
applied to HCF, incubated overnight at 378C with 5% CO2, and
then the cells were cultured with puromycin (2 lg/mL; Sigma-
Aldrich Corp.) for 1 month to exclusively select cells that
expressed the PDGFRa shRNA. Samples from HCF-P and HCF
were collected for Western blot16 and examined for PDGFRa
knockdown. b-actin was used as a loading control. Four
individual shRNA oligo sequences for PDGFRa were tested,
and the cell line containing the shRNA with the maximum
PDGFRa knockdown was selected and used in these studies
(TRCN0000194855; Dana Farber Cancer Institute/Harvard
Medical School).
3D Construct Assembly
Constructs were assembled as previously described.13,17,18
Briefly, the HCFs or HCF-Ps were plated at a density of 106
cells/mL on six-well plates containing polycarbonate mem-
brane inserts with 0.4-lm pores (Transwell; Corning Costar,
Charlotte, NC, USA). Human corneal fibroblasts or HCF-Ps
were cultured for 4 weeks in construct medium (EMEM, 10%
FBS, and a stable vitamin C [VitC] derivative [0.5 mM 2-O-a-D-
glucopyranosyl-L-ascorbic acid; Wako Chemicals USA, Rich-
mond, VA, USA]). Three different groups were tested per cell
type: (1) control or C: construct medium; (2) T1: construct
medium containing 0.1 ng/mL T1; and (3) T3: construct
medium containing 0.1 ng/mL T3. Experiments using all
groups were repeated at least three times, collected, and
processed for reverse transcription–quantitative polymerase
chain reaction (RT-qPCR) and immunofluorescence.
Reverse Transcription–Quantitative Polymerase
Chain Reaction
Total RNA was extracted (Trizol; Thermo Fisher Scientific)
from the constructs, and cDNA was synthesized (High Capacity
cDNA Reverse Transcription Kit; Applied Biosystems, Carlsbad,
CA, USA) according to manufacturer’s protocols. The cDNA
was combined with qPCR master mix (KAPA SYBR Fast qPCR
master mix; KAPA Biosystems, Wilmington, MA, USA) and
primers (Table: SMA,19 PDGFA, PDGFB, PDGFC, PDGFD, or
glyceraldehyde 3-phosphate dehydrogenase [GAPDH]20), and
then amplified (Mastercycler ep realplex real-time PCR system;
Eppendorf, Hauppauge, NY, USA) with the following thermal
cycling conditions: 2 minutes at 508C, 10 minutes at 958C, 40
cycles of 15 seconds at 958C, and 1 minute at 608C. GAPDH, an
endogenous control, was used to normalize target genes. The
primers for each gene were prepared by the CCIB DNA Core
Facility at Massachusetts General Hospital (Cambridge, MA,
USA), and the sequences are given in the Table below. The
relative gene expression of the growth factors was calculated
by using the comparative Ct method.21
Migration Assay
Human corneal fibroblasts or HCF-Ps were cultured in six-well
cell culture plates. After growing to confluence, a scratch was
made in the middle of the well using the end of a 200-lL
pipette tip. Three different groups were examined in serum-
free construct media per cell type: (1) control: no growth
factors; (2) T1: 0.1 ng/mL T1; and (3) T3: 0.1 ng/mL T3. The
cells were imaged using a brightfield microscope (Nikon
E8000; MicroVideo Instruments, Avon, MA, USA) at 0 and 24
hours, and were quantified using ImageJ (version 5.2; https://
imagej.nih.gov/ij/ provided in the public domain by National
Institutes of Health, Bethesda, MD, USA). The percent
migration was calculated by measuring the area without cells
at 0 and 24 hours and then dividing by the corresponding 0-
hour value, then multiplying by 100.
Immunofluorescence Staining
The constructs were collected and processed for immunoflu-
orescence, as previously described.13,17,18 In brief, constructs
were fixed in 4% paraformaldehyde for at least 24 hours,
placed in blocking buffer (1% bovine serum albumin [BSA] and
0.1% Triton-X [Sigma-Aldrich Corp.]) for 1 hour, and incubated
overnight at 48C with primary antibody against SMA (Dako
North America, Carpinteria, CA, USA) in blocking buffer. The
next day, constructs were washed and incubated overnight at
48C with secondary antibody (donkey anti-mouse IgG-FITC;
Jackson ImmunoResearch, West Grove, PA, USA) in blocking
buffer. TO-PRO-3 (Thermo Fisher Scientific) was used as a
marker of all cell nuclei. Constructs were washed, mounted
TABLE. List of SYBR Green Primer Sequences Used for RT-qPCR
Growth Factor Forward Sequences Reverse Sequences
SMA GGTGACGAAGCACAGAGCAA CAGTTGGTGATGATGCCATGTT
PDGFA GGTGGTCACAGGTGCTTTTT AAACCACTTAAGGCTCTCAGGA
PDGFB TGAGAAAGATCGAGATTGTGCG GGGCTTCGGGTCACAGG
PDGFC GAATGTCAATGTGTCCCAAGCA TGCTCCCTCTGCACACACAG
PDGFD ATTTGGCAGGCCATCATAGA CCACAATTGACAACTGGCTTC
GAPDH GAAGGTGAAGGTCGGAGTCA GACAAGCTTCCCGTTCTCAG
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(Vectashield; Vector Laboratories, Burlingame, CA, USA),
observed, and photographed with either a fluorescent
microscope (Nikon E8000; MicroVideo Instruments) for the
23 images or a confocal microscope (TCS-SP2; Leica Micro-
systems, Bannockburn, IL, USA) for the 403 images.
All images were acquired under identical photographic
conditions for all treatment groups, and the brightness/
contrast was kept constant. To quantify the amount of SMA
in each slide, the area of staining in each slide was measured by
ImageJ using the 23 images, which allowed for the complete
view of the entire construct. The value obtained for the
untreated control samples was considered to be background.
The final amount of SMA staining for T1 and T3 was calculated
by subtracting the background value from the T1 or T3 value.
Three constructs per condition and cell type were examined.
Construct thickness was measured with the confocal micro-
scope (403), beginning with the first cell visible at the top of
the construct and the last cell visible at the bottom. Three
constructs per condition and cell type were examined, and
four readings from different areas of each construct were
recorded. The mean of these readings was then calculated and
graphed.
Statistical Analysis
All experiments were performed in triplicate and analyzed for
statistical significance (P < 0.05: GraphPad Prism version 5a;
GraphPad Software, Inc., La Jolla, CA, USA) with either
Student’s t-test or ANOVA followed by Tukey’s post hoc test.
RESULTS
Generation of a Stable PDGFRa Cell Line
To begin our examination of the effect of PDGF signaling on
TGFb-mediated corneal SMA expression, we generated HCF
that had PDGFRa expression permanently knocked down
(HCF-P). As seen in Figure 1A, both the mature (170 kDa) and
immature (160 kDa) bands of the dimeric form of PDGFRa22
were visible for the control HCF, while it was greatly reduced
in HCF-P. This result was further confirmed by image analysis
(Fig. 1B), which showed that PDGFRa expression was
significantly reduced (P < 0.05) in HCF-P when compared to
HCF.
Comparison of SMA RNA Expression and
Construct Thickness
In Figure 2A, SMA mRNA expression was examined by RT-
qPCR in HCF and HCF-P constructs in response to T1 or T3.
Upon T1 stimulation, SMA expression was significantly
increased in both HCF (*P < 0.05) and HCF-P (**P < 0.01)
when compared to their respective controls; however, with
T3, a differential response was observed between the two cell
types. In HCF, the SMA mRNA expression remained similar to
its control, whereas, in HCF-P, as with T1 stimulation, T3
increased SMA mRNA expression significantly, as compared to
its control (**P < 0.01). This suggests that PDGFRa plays a
critical role in the stimulation of SMA by T3.
Figure 2B compares the mean construct thickness of both
HCF and HCF-P in response to T1 or T3. As seen in the graph,
HCF produced a significantly thicker construct than HCF-P
overall (**P < 0.01). As expected, the thickness of T1- and T3-
treated HCF constructs was significantly greater than that of
FIGURE 1. Graph and Western blot showing PDGFRa expression in
HCF and HCF-P cell line. Platelet-derived growth factor receptor a
expression significantly decreased in the HCF-P as compared with HCF
(*P < 0.05, n ¼ 3). Representative Western blot shows PDGFRa
expression characterized by bands at 170 kDa (mature) and 160 kDa
(immature). In the HCF, these bands are prominent; however, in HCF-P,
these bands are less intense, indicating that the PDGFRa has been
knocked down. b-actin (42 kDa) was used as the loading control.
FIGURE 2. Comparison of SMA mRNA expression and mean thickness of constructs in HCF and HCF-P cell line treated with Control (no growth
factors), TGF-b1 (T1), or TGF-b3 (T3). (A) Graph of RT-qPCR of SMA expression in HCF and HCF-P. Upon T1 stimulation, SMA expression increased
in both cell types (*P < 0.05, **P < 0.01) compared with their respective Control. With T3 stimulation, SMA expression for the HCF remained
similar to Control level; however, it increased (**P < 0.01) in HCF-P compared to its Control. (B) Graph of the mean thickness of the HCF and HCF-P
constructs. In HCF, T1 and T3 produced significantly thicker constructs (*P < 0.05) when compared to the untreated Control. The human corneal
fibroblast-P in contrast had significantly thinner constructs (**P < 0.01) when compared to HCF cells even in the presence of T1 and T3.
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HCF controls (*P < 0.05); however, neither T1 nor T3 had any
effect on the HCF-P construct thickness, compared to HCF-P
controls.
Visualization of SMA Using Immunofluorescence
In order to visualize the presence of SMA in HCF (Fig. 3) and
HCF-P (Fig. 4) constructs, as well as to quantify the amount of
SMA staining, immunofluorescence was performed on each of
the replicates. T1-treated samples had higher amounts of SMA
staining (Fig. 3B) when compared to both the control (Fig. 3A)
and T3-treated samples (Fig. 3C). When the area of SMA
staining in each of the replicates was measured using ImageJ
(Figs. 3A–C insets, 3D), SMA staining in T3-treated HCF
constructs was found to be ~95% (*P < 0.05) lower than in
T1-treated samples (Fig. 3D).
However, in HCF-P constructs (Fig. 4), both T1 (Fig. 4B)
and T3 (Fig. 4C) showed an increase in the amount of SMA
staining when compared to their control (Fig. 4A). No
significant difference was noted between T1 and T3
treatment when the amount of SMA staining was quantified
(Figs. 4A–C, insets, 4D). Therefore, in these samples, T3
increased the amount of SMA-staining in HCF-P cells, while it
failed to do so in regular HCF.
Comparison of RNA Expression of PDGF Isoforms
Since our results suggested that PDGFRa plays an important
role in the differential effect of T1 and T3, we then examined
the expression of various PDGF ligands (PDGFA, PDGFB,
PDGFC, and PDGFD) in both cell types in response to T1 or
T3, in the hopes that these ligands may help in determining
the dramatic difference between treatments. In both HCF and
HCF-P, no change was noted in the mRNA expression of
PDGFA (Fig. 5A) and PDGFB (Fig. 5B), except for a slight
decrease in PDGFB when cells were stimulated with T3. In
both cells types, T1 increased the expression of PDGFC (Fig.
5C) and PDGFD (Fig. 5D); however, T3 failed to stimulate the
FIGURE 3. Smooth muscle actin immunofluorescence staining of HCF constructs: (A) Control: no growth factors, (B) T1: TGF-b1, and (C) T3: TGF-
b3. Images were taken at 403 and 23 (insets). The 23 images were used for image analysis as it shows the entire surface area of the construct. (D)
Graph of the area of SMA staining in square pixels measured using ImageJ, background corrected to Control. After 4 weeks, T3 resulted in
significantly lower SMA expression than that of T1 (blue¼ DAPI; red ¼ SMA; n ¼ 3, *P < 0.05).
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expression of PDGFC and only slightly decreased the
expression of PDGFD. For comparing the treatment groups
within the same cell line, ANOVA followed by Tukey’s post
hoc test was used. Student’s t-test was used for comparing
individual gene expression between HCF and HCF-P (Fig. 5E).
If P < 0.05, then ‘‘y,’’ and if no significance, then ‘‘n.’’
PDGFRa Knockdown Inhibited Cell Migration
A migration assay was performed to assess the functional effect
of knocking down PDGFRa. Figure 6 shows the images of HCF
(Fig. 6A) and HCF-P (Fig. 6B) in response to T1 or T3 at day 0,
immediately after a pipette scratch (Figs. 6A, 6B, 6Ba, 6Bc,
6Be), and 24 hours after the scratch (Figs. 6A, 6B, 6Bb, 6Bd,
6Bf). For control samples (Figs. 6Aa–b, 6Ba–b, 6C), the percent
migration for the HCF-P was significantly lower than that of
HCF (*P < 0.05). In the HCF samples, significantly faster
migration (*P < 0.05) was observed with T1 (Figs. 6Ac–d, 6C)
or T3 (Figs. 6Ae–f, 6C) treatment compared to control (Figs.
6Aa–b, 6C). Interestingly, T1- and T3-treated HCF-P (Figs. 6Bc–
d, 6Be–f, 6C) had no significant difference when compared to
the control (Figs. 6Ba–b, 6C), suggesting that T1 and T3’s effect
on migration is dependent on PDGFRa.
DISCUSSION
In this study, we hypothesized that T1 and T3 induced
diametrically opposed responses in HCF by differentially
activating PDGFRa. To test this hypothesis, PDGFRa was
permanently knocked down in HCF-P. These cells were grown
either on plates or in our 3D cell-culture model, stimulated in
response to T1 or T3, and examined for SMA mRNA expression
and protein localization, as well as cell migration. Our data
showed that in HCF, T1 significantly stimulated SMA mRNA
expression, while T3 had little, if any, effect compared with
control (Figs. 2A), which is in agreement with our previous
papers14,23; however, in HCF-P, both T1 and T3 significantly
FIGURE 4. Smooth muscle actin immunofluorescence staining of HCF-P constructs: (A) Control: no growth factors, (B) T1: TGF-b1, and (C) T3:
TGF-b3. Images were taken at 403 and 23 (insets). The 23 images were used for image analysis as it shows the entire surface area of the construct.
(D) Graph of the area of SMA staining in square pixels measured using ImageJ, background corrected to Control. After PDGFRa knockdown in HCF,
T3 stimulated SMA at a level comparable to T1 (blue ¼ DAPI; red¼ SMA; n ¼ 3).
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increased mRNA SMA expression to ~3 times that of control
HCF-P (Fig. 2A). These results were confirmed by immunoflu-
orescence results (Figs. 3, 4).
To determine if the difference in T1 and T3’s effect on SMA
levels was due to the stimulation of PDGF isoforms, we
examined the expression of all four PDGF isoforms (A, B, C,
and D) in both cell types (Fig. 5). Interestingly, PDGFC (Fig.
5C), which has been shown to play an important role in the
regulation of fibrosis in different organs,24,25 notably increased
in both HCF and HCF-P upon T1 stimulation. However, no
significant difference was apparent with any of the PDGFs
upon T3 stimulation when compared to controls for both cell
types. Therefore, since PDGFC has been found to regulate
fibrosis in various organs,24,25 T1 may be involved in fibrosis
through PDGFC in HCF. Platelet-derived growth factor C also
has been shown to activate both PDGFRa and PDGFRab,26
which may explain the residual increase in PDGFC expression
in HCF-P. Therefore, our results suggest that in normal HCF,
T1’s high SMA expression may be through its high PDGFC
stimulation, while T3 fails to stimulate PDGFC, thus leading to
low SMA expression. However, this fails to explain T3’s role in
stimulating SMA in HCF-P, which leads us to believe that T3
may be acting through a different mechanism. Further studies
are required to understand these relationships; however, we
feel these results are quite exciting, in that they are the first
data we have obtained that may begin to explain the disparate
effects of T1 and T3.
Finally, to look at the functional differences between the
two cell types, we looked at construct thickness and cell
migration. In previous papers, we have used the thickness of
the construct as a measure of the amount of ECM produced
and showed that our 3D cell culture model produced a matrix
that had a similar structure to the human stroma and contained
Collagen type I and V.23 Measuring the thickness of the
FIGURE 5. Comparison of RNA expression of PDGF isoforms in HCF and HCF-P cell line treated with Control (no growth factors), TGF-b1 (T1), or
TGF-b3 (T3): (A) PDGFA, (B) PDGFB, (C) PDGFC, and (D) PDGFD. GAPDH was used as the housekeeping gene. Expressions for each cell line were
normalized to that of their respective untreated control. (E) Table showing the results of t-tests performed by comparing all the treatment groups
with each other (n ¼ 6, ‘‘y’’ ¼ P < 0.05, ‘‘n’’ ¼ P > 0.05).
Absence of PDGFRa Makes TGFB3 Stimulate SMA IOVS j February 2017 j Vol. 58 j No. 2 j 1184
constructs in this paper, we found that both T1- and T3-treated
cells produced a thicker construct than their untreated control
(Fig. 2B). This may be due to the effects of TGFB’s mitogenic
properties.1 The human corneal fibroblast-P constructs, in
contrast, were significantly thinner than HCF constructs (Fig.
2B) and also had a slower migration rate than HCF (Fig. 5B). We
believe this might be due to the fact that PDGFRa is strongly
associated with the proliferation and migration of cells.27,28
Interestingly, neither T1 nor T3 had an effect on HCF-P
migration or construct thickness. According to the literature,28
both PDGFRa and PDGFRb stimulate fibroblast migration;
however, it appears that PDGFRb does not compensate for the
loss of PDGFRa in our model. These results are consistent with
our biochemical results that indicated that PDGFRa played a
major role in determining T3’s mechanism of action in
stimulating SMA (Figs. 2, 3).
To summarize, in this present study we have captured the
difference in function of T1 and T3 using our 3D cell culture
model. We also showed that the presence or absence of
PDGFRa affects T3’s ability to stimulate SMA. We believe
understanding this relationship between PDGFRa and T3 may
be the first step toward developing T3 as an antiscarring
therapy for the cornea.
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